
    
      Inclusion Criteria

        -  Age 55-80

        -  70 Participants with Intermediate or Advanced AMD

        -  70 participants with no ocular signs of AMD

        -  Willing to give written informed consent, make the required study visits, and follow
           instructions

        -  Any race and either sex

      Exclusion Criteria

        -  Current history of a medical condition that would preclude scheduled study visits or
           completion of the study (e.g., unstable cardiovascular disease, unstable pulmonary
           disease, chronic hepatitis, or AIDS).

        -  Current or history of an ophthalmic disease in the study eye (other than AMD) that would
           likely compromise or during follow-up could likely compromise the visual acuity of the
           study eye (e.g., amblyopia, uncontrolled glaucoma with an IOP > 30mmHg, ischemic optic
           neuropathy, proliferative diabetic retinopathy, clinically relevant nonproliferative
           diabetic retinopathy, clinically relevant diabetic macular edema, significant active
           uveitis).

        -  Clinical signs of myopic retinopathy, or a refraction of > -8 diopter power in current
           prescription

        -  Aphakic or psuedophakic patients may be enrolled if there is no funduscopic evidence of
           degenerative myopia present and if there is no medical history prior to the patient's
           cataract surgery of either myopic retinopathy or a refraction of > -8 diopters.

        -  Intraocular surgery in study eye (eye to be treated) within 60 days prior to enrollment

        -  Presence of a scleral buckle in the study eye

        -  Currently participating or has participated in a clinical trial that utilized an
           investigational drug or treatment within 30 days prior to administration of study
           medication. Daily vitamins and/or mineral therapy are allowed.

        -  Known medical history of allergy or sensitivity to any component of the drug formulation
           and/or fluorescein dye that is clinically significant in the investigator's opinion.

        -  Patient is on oral anticoagulant therapy of Coumadin
    
  